drugset / Trial / NCT04868253
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
Phase 2/3
Unknown
25 enrolled
Rose Research Center, LLC
Embera NeuroTherapeutics, Inc. · collabFoundation for a Smoke Free World INC · collab
NaSingle-groupOpen-labelTreatment
Summary
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.
Timeline
- Start
- 2021-05-19
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metyrapone | Small molecule | 720 mg | — |
| Subject | oxazepam | Small molecule | 24 mg | — |